Search Menu

Archives

HIV+ survey on a cure: please support with 10 minutes

This short survey is looking for community views from the UK and internationally to help shape future research

IAS 2014: news from Melbourne

Short reports and links to news at the 20th World AIDS Conference: cure research, PrEP (do you swallow?), pipeline report, HIV and children, HIV-related complications, activists protest Gilead’s price for sofosbuvir and global TasP…

Pipeline report 2014

Latest review of latest developments in HIV, HCV and TB: pipeline drugs, vaccines, cure strategies and diagnostics

Avoiding and managing side effects (Macedonian

Please click title link for the download page.

New ARV prescribing guidelines for London (2014)

Broadly good, but a few surprises: raltegravir alternative to efavirenz, limited use of generics, no need to switch stable patients…

Guide to Avoiding and Managing Side Effects (Latvian)

Please click title link for the download page.

Introduction to combination therapy (Latvian)

Please click title link for the download page.

HIV, pregnancy and women’s health (Latvian)

Please click title link for the download page.

Latvian guides now include HIV and pregnancy

A new Latvian translation of the i-Base guide to HIV, Pregnancy and Women’s Health is now online. This is the fourth i-Base guide to be translated into Latvian, in collaboration with Association HIV.LV and the EATG COPE project. HIV, pregnancy …

Hepatitis C for people living with HIV (Latvian)

Please click title link for the download page.

START study open DSMB report (May 2014)

The latest open report from the Data and Safety Monitoring Board (DSMB) for the international randomised START study is now online. START looks at the risks and benefits of immediate treatment (at any CD4 count above 500 cells/mm3) compared to …

Generic ARVs in the UK – background paper for drug commissioning

Leaflet in PDF format (82 Kb) New commissioning guidelines for London – April 2014. Introduction by i-Base This paper was originally drafted in 2012 as a discussion paper for the London HIV Consortium HIV and Drugs sub-committee, which I have been …

May/June HTB now online

Reports from EASL, BHIVA and CROI: new hepatitis C drugs, including pricing and UK access; ARVs in pregnancy; early use in babies; tenofovir in Zambia; US guidelines for treatment and PrEP; all this and more…

PIVOT study: protease inhibitor monotherapy

Note: the PIVOT study is now closed. Results were presented at CROI 2014 and the BHIVA/BASHH in 2014. PIVOT stands for “Protease Inhibitor monotherapy Versus Ongoing Triple-therapy in the long term management of HIV infection”. The PIVOT study is the largest UK trial for …

STARHS test

STARHS – this is a type of HIV test that can indicate whether you are likely to have been infected within the last six months. STARHS stands for Serological Testing Algorithm for Recent HIV Seroconversion. In the UK this test is now …

Credits

This resource was written and compiled by Simon Collins for HIV i-Base. It is part of the i-Base advocacy training manual. Third edition (May 2014). This booklet is one section of the i-Base training manual for advocates, available online (www.i-Base.info). …

SCART study: selumetinib as potential treatment for HIV-related KS

SCART is a UK study for HIV-related Kaposi’s Sarcoma (KS). It uses an experimental cancer drug called selumetinib. KS is a type of cancer that is more common in HIV positive people although it is much less common now that …

HIV Bilten (HTB West Balkans, BMCS)

Please click title link for the download page.

Замена терапии и лекарственная устойчивость (Guide to Changing Treatment)

Замена терапии и лекарственная устойчивость  – Февраль 2013  (Changing Treatment) (PDF) Перевод: А. Лебедев, НИИ вирусологии им. Д.И. Ивановского МЗ РФ, г. Москва e-mail: swan_236@mail.ru. Работа выполнена как составная часть образовательных программ в рамках проекта «Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)» …

EASL 2014 – European Liver Meeting in London

A ‘rapid report’ covering the numerous new and upcoming drugs for hepatitis C – plus new guidelines from WHO and EASL…

Post navigation